PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research ...

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform gene editing in non-liver tissues, including skeletal muscle, using a ...

In the mid-1990s, Hiroyuki Nakai, now an adeno-associated virus (AAV) researcher at the Oregon Health and Science University, moved to the United States. Nakai quickly became fascinated with the ...

Adeno-associated virus (AAV) vectors have become widely recognized as a fundamental tool in gene therapy, primarily due to their potential as a delivery system for the treatment of genetic disorders.

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...

Joseph La Barge has been mulling over the limitations of gene therapy for some time. So, when he left his position at Spark Therapeutics, having watched the company grow from its start in borrowed ...

Dhimiter Bello, Sc.D., M.Sc. (Chair) Jonathan Hill, Ph.D. (industry on site advisor) Soumita Das, Ph.D. Jonghan Kim, Ph.D. Brief Abstract: Adeno-Associated Virus (AAV) vectors are being used in the ...

The quest to restore hearing and balance function has long been a central challenge in medicine, particularly for genetic forms of inner ear disorders that have no effective cure. While treatments ...